• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AVIR

    Atea Pharmaceuticals Inc.

    Subscribe to $AVIR
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: ateapharma.com

    Peers

    $ALBO
    $KZR
    $OYST

    Recent Analyst Ratings for Atea Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    10/20/2021$60.00 → $20.00Outperform
    SVB Leerink
    10/20/2021$61.00 → $16.00Overweight → Neutral
    JP Morgan
    See more ratings

    Atea Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirsch Arthur S

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/24/25 6:52:21 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Kirsch Arthur S claimed ownership of 45,710 shares (SEC Form 3)

      3 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/24/25 6:47:18 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Hammond Janet Mj was granted 11,250 shares, covered exercise/tax liability with 14,134 shares and converted options into 46,800 shares, increasing direct ownership by 117% to 81,388 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:21 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Corcoran Andrea covered exercise/tax liability with 16,102 shares, converted options into 44,367 shares and was granted 10,500 shares, increasing direct ownership by 6% to 717,307 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:15 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO, and Chairman Sommadossi Jean-Pierre was granted 99,517 shares, covered exercise/tax liability with 88,601 shares and converted options into 173,467 shares, increasing direct ownership by 158% to 300,940 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:09 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Vavricka John converted options into 33,333 shares, was granted 8,750 shares and covered exercise/tax liability with 11,517 shares, increasing direct ownership by 142% to 52,081 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:20 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Accounting Officer Foster Wayne converted options into 33,333 shares, was granted 8,000 shares and covered exercise/tax liability with 12,062 shares, increasing direct ownership by 140% to 50,128 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:06 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Horga Maria Arantxa converted options into 41,533 shares, was granted 9,750 shares and covered exercise/tax liability with 16,071 shares, increasing direct ownership by 137% to 60,876 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:17 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

      4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 2:30:36 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 8:03:19 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

      4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 2:30:36 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 8:03:19 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form DEF 14A filed by Atea Pharmaceuticals Inc.

      DEF 14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      4/29/25 5:00:56 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Atea Pharmaceuticals Inc.

      SCHEDULE 13D/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      4/17/25 12:23:57 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure

      8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      4/17/25 8:06:48 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Atea Pharmaceuticals Inc.

      DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      4/3/25 4:50:41 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Atea Pharmaceuticals Inc.

      DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      4/1/25 9:21:44 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Atea Pharmaceuticals Inc.

      8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      4/1/25 9:19:17 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Atea Pharmaceuticals Inc.

      DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      3/26/25 5:15:50 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DFAN14A filed by Atea Pharmaceuticals Inc.

      DFAN14A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      3/26/25 2:30:31 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Atea Pharmaceuticals Inc.

      DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      3/24/25 6:16:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Atea Pharmaceuticals Inc.

      8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      3/24/25 6:10:08 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/15/24 10:34:54 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/12/24 9:50:14 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/15/24 11:35:08 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/15/24 9:15:47 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/14/24 8:02:48 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/13/24 4:58:55 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/13/24 4:30:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/9/24 8:35:54 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/7/24 9:25:42 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Atea Pharmaceuticals Inc.

      SC 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/7/24 9:14:41 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

              Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Neededin Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 BOSTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the d

      5/7/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

      Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opi

      5/1/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the full results from the Phase 2 clinical study of Atea's regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV) infection will be presented at the European Association for the Study of the Liver (EASL) Congress 2025. In addition, pharmacokinetic and safety results supporting the regimen's profile will also be presented. The EASL Congres

      4/23/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

      Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US New Next-Generation HCV Therapies are Needed to Improve Patient Outcomes BOSTON, April 09, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the first patient has been dosed in C-BEYOND, Atea's Phase 3 trial eva

      4/9/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

      BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement: The Atea Board of Directors and management team have recently taken several decisive actions to enhance shareholder value, including: Launching a comprehensive review of strategic opportunities – In the fourth quarter of 2024, Atea engaged an independent global investment bank to assist the Company in identifying potential opportunities to enhance shareholder value, including the exploration of strategic part

      3/26/25 1:58:05 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Issues Statement Regarding Director Nominations

      BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirmed receipt of a notice from Bradley L. Radoff that he intends to nominate three director candidates to stand for election to the Atea Board of Directors at the Company's 2025 Annual Meeting of Stockholders.         The Atea Board of Directors and management team engage in regular communications with Atea's shareholders and regularly evaluate the Company's strategy to enhance shareholder value. The Nominating and Corporate Governance Co

      3/21/25 5:54:16 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

      BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the poster presentation of bemnifosbuvir preclinical data at the 38th International Conference on Antiviral Research (ICAR) 2025 taking place March 17-21, 2025 in Las Vegas, Nevada. "The results presented at ICAR highlight Atea's deep scientific expertise in antiviral drug development by demonstrating metabolism of nucleotide prodrugs, such as bemnifosbuvir, is highly cell-line dependent and cell model selection needs to be taken i

      3/19/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "I am pleased to share that we recently had a successful End-of-Phase 2 meeting with

      3/6/25 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

      BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals we

      2/27/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

      Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opi

      5/1/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "I am pleased to share that we recently had a successful End-of-Phase 2 meeting with

      3/6/25 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

      BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals we

      2/27/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

      Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem

      11/7/24 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

      BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir

      10/31/24 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

      Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial resul

      8/7/24 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

      BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.atea

      7/31/24 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

      Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended Mar

      5/14/24 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

      BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.at

      5/7/24 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

      Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board (DSMB) Planned for 1H'24 with Topline Results Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quar

      2/28/24 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

      BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c

      2/10/22 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

      BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences. "We are very pleased to welcome Claudio to the Atea team. Claudio's extensive expertise and experience in medical affairs with a focus on COVID-19, hepatitis and HIV as part of his overall interest in serious viral infectious diseases, will complement and s

      6/15/21 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

      BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership. "We are honored to welcome Dr. Adams to our Board of Directors, as his unique experience as Surgeon General during the COVID-19 pandemic will undoubtedly help guide Atea as we continue to advance our ant

      5/20/21 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Atea Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously

      8/13/24 7:25:26 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight

      8/10/23 6:17:18 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

      JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

      3/2/22 10:09:39 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Atea Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Market Perform and set a new price target of $9.00 from $10.00 previously

      3/1/22 5:04:11 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Atea Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Market Perform and set a new price target of $10.00 from $11.00 previously

      2/16/22 5:17:53 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Atea Pharmaceuticals from Equal-Weight to Underweight and set a new price target of $7.00 from $14.00 previously

      1/6/22 8:15:44 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by SVB Leerink

      SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Mkt Perform

      11/18/21 7:16:40 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Market Perform and set a new price target of $11.00

      11/18/21 6:18:51 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Atea Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $60.00 previously

      10/20/21 9:15:33 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by JP Morgan with a new price target

      JP Morgan downgraded Atea Pharmaceuticals from Overweight to Neutral and set a new price target of $16.00 from $61.00 previously

      10/20/21 6:23:08 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care